Tubulis
Nuformix proposes acquisition of Biovara
The companies focus on fibrosis and oncology, and novel treatments for respiratory conditions, respectively
argenx to acquire Unnatural Products for $1.15bn
argenx already holds a minority stake in UNP and will acquire all remaining shares
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Klick Health acquires Oxford PharmaGenesis
The move expands Klick’s scientific expertise in oncology and rare diseases
Zymeworks to acquire Theravance Biopharma in deal worth $929m
The acquisition will give the company access to a treatment for COPD